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INTRODUCTION
Ovarian cancer is the second most common gyne-
cological cancer in western women and also in In-
donesia.1,2 It varies widely in frequency among dif-
ferent geographic regions and ethnic groups. The
majority of cases are sporadic, and only 5% to 10%
of ovarian cancers are familial.3 Ovarian cancer,
rare before age 40, increases steeply there after
and peaks at ages 65-75. Incidence and mortality
rates are higher among white women than among
Abstract
Objective: To evaluate Risk of Malignancy Index (RMI) as a triage
tool for ovarian cancer in Dr. Cipto Mangunkusumo Hospital.
Method: This is a retrospective study conducted from January 2008-
December 2012 in patients diagnosed with ovarian mass. Patients
admitted for surgery due to ovarian masses were included to this
study. RMI 3 score was calculated based on ultrasonography exami-
nation in Dr. Cipto Mangunkusumo Hospital, CA-125 test and meno-
pausal status. Patients without final pathological report and incom-
plete data were excluded from study. Data were analysed using SPSS
20 to evaluate RMI result and final pathlogical report in benign and
malignant case.
Result: From 882 patients identified with ovarian masses from can-
cer registry, only 99 patients aged 17-70 y.o were included in this
study. Most of the patients were nully-parity (28.3%), non-meno-
pausal women (60.6%), normal body mass index (40.4%), and with
stage IIIC ovarian cancer (33.3%). Ultrasonography examination
showed that most of patients had solid mass and ascites (19.2%).
Meanwhile, CA-125 showed that patients with <35 U/ml were
10.1% and ≥ 35 U/ml were 89.9%. Patients with RMI scores <200
(benign cases) were 19 cases (19.2%) and ≥ 200 (malignant cases)
were 80 cases (80.8%). Meanwhile, patients with benign final patho-
logical report were 23 cases (23.2%) and malignant cases were 76
cases (76.8%). There was no statistical difference in RMI between
benign and malignant cases based on final pathological report.
Conclusion: Our study showed that RMI was not accurate as triage
tool for ovarian cancer in our hospital. Further investigation and
more patients are needed to confirm this study.
[Indones J Obstet Gynecol 2014; 2-1: 50-54]
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Abstrak
Tujuan: Untuk mengevaluasi Risk of Malignancy Index (RMI) sebagai
alat triase kanker ovarium di Rumah Sakit Dr. Cipto Mangunkusumo.
Metode: Penelitian retrospektif ini dilaksanakan dari Januari 2008
sampai Desember 2012 pada pasien yang didiagnosa dengan massa
pada ovarium. Nilai RMI 3 dihitung berdasarkan pemeriksaan ultra-
sonografi di Rumah Sakit Dr. Cipto Mangunkusumo, nilai CA-125 dan
status menopause. Data dianalisis dengan menggunakan SPSS 20 un-
tuk mengevaluasi hasil RMI dan penilaian patologi akhir pada kasus
jinak dan ganas.
Hasil: Dari 882 pasien yang teridentifikasi dengan massa ovarium
dari registrasi kanker, hanya terdapat 99 pasien yang berusia 17-70
tahun yang memenuhi kriteria inklusi. Sebagian besar pasien adalah
pasien bukan nuliparitas (28,3%), belum menopause (60,6%), Indeks
Massa Tubuh normal (40,4%), dan dengan stadium IIIC (33,3%). Pe-
meriksaan ultrasonografi menunjukkan sebagian besar pasien mem-
punyai massa padat dan asites (19,2%). Sementara itu, terdapat
10,1% pasien dengan kadar CA-125 <35 U/ml dan 89,9% dengan CA-
125 ≥ 35 U/ml. Terdapat 19 kasus (19,2%) dengan RMI <200 (jinak)
dan 80 kasus (80,8%) dengan RMI ≥ 200 (ganas). Pemeriksaan pa-
tologi akhir menunjukkan 23 kasus jinak (23,2%) dan 76 kasus ganas
(76,8%). Tidak terdapat perbedaan yang bermakna secara statistik
pada nilai RMI untuk kasus jinak ataupun ganas berdasarkan peme-
riksaan patologi akhir.
Kesimpulan: Penelitian kami menunjukkan bahwa RMI tidak akurat
sebagai alat triase untuk kanker ovarium di rumah sakit kami. Inves-
tigasi lebih lanjut dan lebih banyak pasien diperlukan untuk meng-
konfirmasi penelitian ini.
[Maj Obstet Ginekol Indones 2014; 2-1: 50-54]
Kata kunci: CA-125, Risk of Malignancy Index (RMI), status meno-
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African-American women. Over the last three de-
cades, ovarian cancer incidence has remained sta-
ble in high-risk countries, while an increasing trend
has been reported in low-risk countries.1,4
Factors associated with an increased risk for in-
vasive epithelial ovarian cancer include age, race,
nulliparity, family history of ovarian cancer, and
history of endometrial or breast cancer.4 There is
a weak association between ovarian cancer and age
at natural menopause and among women with
early onset disease. Factors associated with a re-
duced risk are history of one or more full-term
pregnancies, use of oral contraceptives, history of
breast feeding, tubal ligation, and hysterectomy.5
Risk decreased with the number of pregnancies
and sterilization. Use of oral contraceptives signi-
ficantly reduced risk of ovarian cancer and reduced
slightly with duration of use.6-8
Characterization of adnexal masses to identify
patients with malignant ovarian mass preopera-
tively for referral to a cancer center for treatment
has been extensively studied.9,10 The accuracy of
ultrasonography in differentiating between benign
and malignant adnexal masses is proportional to
the expertise of the operator.11,12 Findings sugges-
tive of malignancy in an adnexal mass include a
solid component, thick septations (greater than 2
to 3 mm), bilaterality, Doppler flow to the solid
component of the mass, and presence of ascites.13
CA-125 (MUC16) has provided a useful serum
tumor marker for monitoring response to chemo-
therapy, detecting disease recurrence, distinguish-
ing malignant from benign pelvic masses, and po-
tentially improving clinical trial design.14-16 The
normal value for a CA-125 depend on the lab run-
ning the test. In general, a level above 35 U/ml are
considered abnormal.17
The aims of this study were to evaluate the risk
of malignancy index (RMI) incorporating meno-
pausal status, serum CA-125 levels, and ultrasound
features for discriminating benign from malignant
pelvic masses and to evaluate the performance of
the three different risk of malignancy indices Dr.
Cipto Mangunkusumo Hospital.
METHODS
This is a retrospective study conducted from Ja-
nuary 2008-December 2012 in patients diagnosed
with ovarian mass. Patients admitted for surgery
due to ovarian masses were included to this study.
RMI 3 score was calculated based on ultrasono-
graphy (U) examination in Dr. Cipto Mangunku-
sumo hospital, CA-125 (measured in U/ml) test
and menopausal status (M). Patients without final
pa-thological report and incomplete data were ex-
cluded from study. Data were analyzed using SPSS
20 to evaluate RMI result and final pathological re-
port in benign and malignant case.
Ultrasonography is scored based on five attri-
butes suggestive of malignancy. These attributes
are the presence of solid parts, multilocular cyst,
ascites, bilateral lesions, and intra-abdominal me-
tastases. One point is given for one or no presence
of the attributes, and three points for more than
one attributes. Menopausal woman is given three
points, and non-menopausal woman is given one
point. CA-125 is scored equal to the blood level of
CA-125 (U/ml). RMI score ≥ 200 is considered to
be high is of malignancy, and RMI score <200 is
considered to be low risk of malignancy. RMI score
was evaluated based on final pathologic report as
benign or malignant case. When ovarian mass was
malignant, it was staged based on Federation of Gy-
necology and Obstetrics (FIGO) classification.
RESULT
From 882 patients identified with ovarian masses
from cancer registry, only 99 patients aged 17-70
y.o were included in this study. Most of the patients
were nullyparity (28.3%), non-menopausal women
(60.6%), normal body mass index (40.4%), and
with stage IIIC ovarian cancer (33.3%). There were
no significant difference between benign and ma-
lignant case based on age (p = 0.82), parity (p =
0.09), menopausal status (p = 0.6), and CA-125
mean (p = 0.162). Body Mass Index (BMI) showed
significant difference between benign and malig-
nant case (p = 0.011). See Table 1 and 2.
RMI and CA-125 showed good sensitivity (84.2
and 90.8), but Area Under Curve showed low per-
formance (0.57 and 0.51). Our study showed that
RMI, ultrasonography score, CA-125, and meno-
pausal status has poor performance as triage tool.
RMI3=UxMxCA-125
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Table 1. Patient’s Characteristics.
Variable Benign
(n= 23)
Malignant
(n=76)
p
Age 0.82a
Median 44 47
Minimum 18 17
Maximum 70 68
Parity 0.09a
Mean 3 2
Minimum 0 0
Maximum 9 10
Menopause 0.6b
Yes 8 (8.1%) 31 (31.3%)
No 15 (15.2%) 45 (45.4%)
BMI 0.011b
Underweight 4 (4%) 20 (20.2%)
Normal 16 (16.2%) 24 (24.2%)
Overweight 1 (1%) 10 (10.2%)
Obese I 2 (2%) 19 (19.2%)
Obese II 0 (0%) 3 (3%)
CA-125 0.162a
Mean 1662.4 775.9
Minimum 16.6 13.3
Maximum 23566.0 9537.0
aMann-Whitney U test
bPearson X2 test
Table 2. FIGO Stage
FIGO n = 76
IA 9 (11.8%)
IB 2 (2.7%)
IC 15 (19.8%)
IIA 1 (1.4%)
IIB 5 (6.5%)
IIC 6 (7.9%)
IIIC 33 (43.4%)
IV 5 (6.5%)
 
Figure 1. Receiver Operator Characteristic (ROC) Curve
Shows the Relationship between Sensitivity and Specificity
for RMI, CA 125, Menopausal Status, USG Score.
Table 3. Area Under Curve, Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value for RMI, CA-125,
Menopausal Status, USG Score.
Variable
Histopathological result (n = 99)
AUC Sensitivity Specificity Positive predic-tive value
Negative predic-
tive value
Malignant Benign
RMI ≥ 200 64 16
0.57 84.2 30.4 80.0 36.8
RMI <200 12 7
CA-125 ≥35 U/ml 69 20
0.51 90.8 13.0 77.5 30.0
CA-125 <35 U/ml 7 3
Menopause 31 8
0.53 40.8 65.2 79.4 25.0
Non-menopause 45 15
USG score 3 55 13
0.59 72.4 43.5 80.8 32.2
USG score 1 21 10
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DISCUSSION
Many studies showed that Risk of malignancy in-
dex (RMI) is a valuable tool to differ benign from
malignant ovarian mass. It has been used widely
to help clinician in daily practice encountering
adnexal masses.9,18 RMI is non-invasive and simple
to apply in daily clinical practice.19 RMI has been
through 4 times modification since it was first in-
troduced in 1990 by Jacob et al.20 The last modifi-
cation (RMI 4) was introduced in 2009 by
Yamamoto et al, which is added tumor size in cal-
culation.21
In our study, RMI had good sensitivity (84.2) but
poor specificity (30.4). RMI showed good perfor-
mance as screening tool but poor performance as
triage tool to differ benign from malignant ovarian
mass. Moreover, Area Under Curve of RMI showed
low significance level (0.57). Other study conduc-
ted by Ong C et al in Singapore showed similar re-
sult with our study. Ong C et al concluded that RMI
1, RMI 2, RMI 3, RMI 4 showed no statistical dif-
ference to differ benign from malignant cases in
Southeast Asian population.19
The components of RMI also showed no statis-
tical difference between benign and malignant
case. CA-125 showed the higher sensitivity (90.8)
with the lowest specificity (13.0). This finding is
consistent with other studies. Metaanalysis study
showed that CA-125 has good sensitivity for de-
tection malignant ovarian mass, but poor specifi-
city.22,23 CA-125 level was influenced by several
factors, including age, smoking status, ethnicity,
and history of breast cancer. Meanwhile, history of
previous gynecological operation and obesity lo-
wer the CA-125 level.23
Evaluation of ovarian mass based on ultrasono-
graphy depends on examiner’s experience. Experi-
enced ultrasonography examiner can determine
benign or malignant adnexal mass accurately.24
Van Calster et al showed that 93% of tumor were
correctly categorized as benign of malignant by
pattern recognition.25 Moreover, pattern recogni-
tion was superior than CA-125 to differ benign
from malignant ovarian case.25
There are several limitation in this study, such
as small number of cases. Eventhough, many cases
were identified, only few of them could be analy-
zed. The problems were medical record storage
system. Many medical records were not found to
be reviewed, and few of them with incomplete
data. Others limiting factors in our study included
its retrospecitve nature and limited time to do the
research.
CONCLUSION
Our study showed that RMI was not accurate as
triage tool for ovarian cancer in our hospital. Fur-
ther investigation and more patients are needed to
confirm this study. 
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